Literature DB >> 7773294

A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice.

M Harvey1, H Vogel, D Morris, A Bradley, A Bernstein, L A Donehower.   

Abstract

To test the behaviour of a mutant form of p53 in the presence and absence of wild-type p53 in vivo, we mated p53-deficient mice containing a p53 null allele to transgenic mice containing multiple copies of a mutant p53 gene (Val 135). Animals hemizygous for the endogenous wild-type p53 gene with the mutant transgene exhibited accelerated tumour development and an altered tumour spectrum compared to their non-transgenic counterparts. In contrast, transgenic and non-transgenic animals nullizygous for endogenous p53 developed tumours at the same rate. Thus, the mutant Val-135 p53 allele may act in vivo in a dominant negative manner in the presence of wild-type p53 but does not display gain of function activity in the absence of wild-type p53.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7773294     DOI: 10.1038/ng0395-305

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  53 in total

1.  Mutually compensatory mutations during evolution of the tetramerization domain of tumor suppressor p53 lead to impaired hetero-oligomerization.

Authors:  M G Mateu; A R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

2.  Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas.

Authors:  K M La Perle; S M Jhiang; C C Capen
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

3.  Nine hydrophobic side chains are key determinants of the thermodynamic stability and oligomerization status of tumour suppressor p53 tetramerization domain.

Authors:  M G Mateu; A R Fersht
Journal:  EMBO J       Date:  1998-05-15       Impact factor: 11.598

4.  Protein markers in colorectal cancer: predictors of liver metastasis.

Authors:  C R Berney; R J Fisher; J Yang; P J Russell; P J Crowe
Journal:  Ann Surg       Date:  1999-08       Impact factor: 12.969

Review 5.  The two faces of tumor suppressor p53.

Authors:  M L Smith; A J Fornace
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

6.  Inhibition of stress-inducible kinase pathways by tumorigenic mutant p53.

Authors:  Yoichi Ohiro; Anny Usheva; Shinichiro Kobayashi; Shannon L Duffy; Regan Nantz; David Gius; Nobuo Horikoshi
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

7.  The tumorigenic potential and cell growth characteristics of p53-deficient cells are equivalent in the presence or absence of Mdm2.

Authors:  S N Jones; A T Sands; A R Hancock; H Vogel; L A Donehower; S P Linke; G M Wahl; A Bradley
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

8.  Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy.

Authors:  Olga Catalina Rodriguez; Sujatra Choudhury; Vamsi Kolukula; Eveline E Vietsch; Jason Catania; Anju Preet; Katherine Reynoso; Jill Bargonetti; Anton Wellstein; Chris Albanese; Maria Laura Avantaggiati
Journal:  Cell Cycle       Date:  2012-11-14       Impact factor: 4.534

9.  Gastroesophageal reflux leads to esophageal cancer in a surgical model with mice.

Authors:  Jing Hao; Ba Liu; Chung S Yang; Xiaoxin Chen
Journal:  BMC Gastroenterol       Date:  2009-07-23       Impact factor: 3.067

10.  Mutant p53 mediates survival of breast cancer cells.

Authors:  L Y Lim; N Vidnovic; L W Ellisen; C-O Leong
Journal:  Br J Cancer       Date:  2009-09-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.